Published in J Med Chem on November 16, 2006
ZINC: a free tool to discover chemistry for biology. J Chem Inf Model (2012) 6.57
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des (2013) 2.93
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem (2012) 2.86
Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des (2007) 2.79
Update of TTD: Therapeutic Target Database. Nucleic Acids Res (2009) 2.35
Automated docking screens: a feasibility study. J Med Chem (2009) 2.14
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Molecular shape and medicinal chemistry: a perspective. J Med Chem (2010) 1.91
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem (2008) 1.81
Confidence limits, error bars and method comparison in molecular modeling. Part 1: the calculation of confidence intervals. J Comput Aided Mol Des (2014) 1.78
Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci (2012) 1.72
What do we know and when do we know it? J Comput Aided Mol Des (2008) 1.68
Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol (2009) 1.60
Advances and challenges in protein-ligand docking. Int J Mol Sci (2010) 1.54
Variability in docking success rates due to dataset preparation. J Comput Aided Mol Des (2012) 1.54
Computational methods in drug discovery. Pharmacol Rev (2013) 1.51
HIT: linking herbal active ingredients to targets. Nucleic Acids Res (2010) 1.50
Assessment of ligand-binding residue predictions in CASP9. Proteins (2011) 1.47
How to do an evaluation: pitfalls and traps. J Comput Aided Mol Des (2008) 1.43
CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. J Chem Inf Model (2011) 1.42
FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des (2012) 1.36
Molecular docking screens using comparative models of proteins. J Chem Inf Model (2009) 1.36
Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One (2010) 1.35
Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des (2012) 1.34
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J Comput Aided Mol Des (2008) 1.32
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol (2012) 1.31
Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Surflex-Dock: Docking benchmarks and real-world application. J Comput Aided Mol Des (2012) 1.27
Evaluation of DOCK 6 as a pose generation and database enrichment tool. J Comput Aided Mol Des (2012) 1.22
Bias, reporting, and sharing: computational evaluations of docking methods. J Comput Aided Mol Des (2007) 1.21
Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. J Comput Aided Mol Des (2012) 1.21
Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model (2010) 1.21
Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol Syst Biol (2011) 1.19
Confab - Systematic generation of diverse low-energy conformers. J Cheminform (2011) 1.18
High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput Biol (2009) 1.18
A computational approach to finding novel targets for existing drugs. PLoS Comput Biol (2011) 1.17
Assessment of ligand binding residue predictions in CASP8. Proteins (2009) 1.14
ElectroShape: fast molecular similarity calculations incorporating shape, chirality and electrostatics. J Comput Aided Mol Des (2010) 1.14
NNScore 2.0: a neural-network receptor-ligand scoring function. J Chem Inf Model (2011) 1.12
Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation. J Comput Aided Mol Des (2009) 1.11
Customizing scoring functions for docking. J Comput Aided Mol Des (2008) 1.11
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One (2010) 1.10
FINDSITE(comb): a threading/structure-based, proteomic-scale virtual ligand screening approach. J Chem Inf Model (2012) 1.09
BSP-SLIM: a blind low-resolution ligand-protein docking approach using predicted protein structures. Proteins (2011) 1.08
Application of 3D Zernike descriptors to shape-based ligand similarity searching. J Cheminform (2009) 1.08
DOCK 6: Impact of new features and current docking performance. J Comput Chem (2015) 1.07
Exploiting ordered waters in molecular docking. J Med Chem (2008) 1.07
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc Natl Acad Sci U S A (2013) 1.06
Docking screens: right for the right reasons? Curr Top Med Chem (2009) 1.05
Optimal assignment methods for ligand-based virtual screening. J Cheminform (2009) 1.03
A machine learning-based method to improve docking scoring functions and its application to drug repurposing. J Chem Inf Model (2011) 1.03
Evaluating docking programs: keeping the playing field level. J Comput Aided Mol Des (2008) 1.02
Implementation and evaluation of a docking-rescoring method using molecular footprint comparisons. J Comput Chem (2011) 1.02
Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test. J Comput Aided Mol Des (2012) 1.01
Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol (2013) 1.01
rDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acids. PLoS Comput Biol (2014) 1.01
Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. J Med Chem (2011) 1.01
Effects of inductive bias on computational evaluations of ligand-based modeling and on drug discovery. J Comput Aided Mol Des (2007) 1.00
Systematic exploitation of multiple receptor conformations for virtual ligand screening. PLoS One (2011) 0.99
How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Eur Biophys J (2010) 0.99
Comprehensive prediction of drug-protein interactions and side effects for the human proteome. Sci Rep (2015) 0.99
Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. J Phys Chem B (2012) 0.99
Ligand pose and orientational sampling in molecular docking. PLoS One (2013) 0.99
An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular Dynamics. J Chem Theory Comput (2009) 0.98
Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharmacol (2013) 0.96
Statistical potential for modeling and ranking of protein-ligand interactions. J Chem Inf Model (2011) 0.95
Molecular modeling and ligand docking for solute carrier (SLC) transporters. Curr Top Med Chem (2013) 0.95
Rationalizing tight ligand binding through cooperative interaction networks. J Chem Inf Model (2011) 0.95
ALiBERO: evolving a team of complementary pocket conformations rather than a single leader. J Chem Inf Model (2012) 0.94
High selectivity of the γ-aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach. J Biol Chem (2012) 0.94
Conformational flexibility in immunoglobulin E-Fc 3-4 revealed in multiple crystal forms. J Mol Biol (2009) 0.94
The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci (2011) 0.94
Experimental validation of FINDSITE(comb) virtual ligand screening results for eight proteins yields novel nanomolar and micromolar binders. J Cheminform (2014) 0.94
High-Throughput parallel blind Virtual Screening using BINDSURF. BMC Bioinformatics (2012) 0.94
Protein pharmacophore selection using hydration-site analysis. J Chem Inf Model (2012) 0.93
Are predicted protein structures of any value for binding site prediction and virtual ligand screening? Curr Opin Struct Biol (2013) 0.93
Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. ChemMedChem (2011) 0.93
Binding-site assessment by virtual fragment screening. PLoS One (2010) 0.93
The influence of negative training set size on machine learning-based virtual screening. J Cheminform (2014) 0.92
Exploring chemical space for drug discovery using the chemical universe database. ACS Chem Neurosci (2012) 0.92
LIGSIFT: an open-source tool for ligand structural alignment and virtual screening. Bioinformatics (2014) 0.91
The influence of the inactives subset generation on the performance of machine learning methods. J Cheminform (2013) 0.91
Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening. J Chem Inf Model (2010) 0.91
Support vector regression scoring of receptor-ligand complexes for rank-ordering and virtual screening of chemical libraries. J Chem Inf Model (2011) 0.91
Ligand-based virtual screening approach using a new scoring function. J Chem Inf Model (2012) 0.90
Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors. J Comput Aided Mol Des (2015) 0.90
Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling. J Comput Aided Mol Des (2014) 0.89
Does your model weigh the same as a duck? J Comput Aided Mol Des (2011) 0.89
Improving molecular docking through eHiTS' tunable scoring function. J Comput Aided Mol Des (2011) 0.89
Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf Model (2009) 0.88
VSDMIP 1.5: an automated structure- and ligand-based virtual screening platform with a PyMOL graphical user interface. J Comput Aided Mol Des (2011) 0.88
Compound activity prediction using models of binding pockets or ligand properties in 3D. Curr Top Med Chem (2012) 0.87
Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem (2012) 0.87
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. J Med Chem (2016) 0.87
PoLi: A Virtual Screening Pipeline Based on Template Pocket and Ligand Similarity. J Chem Inf Model (2015) 0.86
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J Med Chem (2012) 0.86
Genome-scale screening of drug-target associations relevant to Ki using a chemogenomics approach. PLoS One (2013) 0.86
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. PLoS One (2012) 0.86
Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41. J Comput Chem (2013) 0.85
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Solvent-accessible surfaces of proteins and nucleic acids. Science (1983) 11.29
Reduced surface: an efficient way to compute molecular surfaces. Biopolymers (1996) 10.62
Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov (2004) 8.10
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem (2004) 7.96
A geometric approach to macromolecule-ligand interactions. J Mol Biol (1982) 5.71
The PDBbind database: methodologies and updates. J Med Chem (2005) 5.53
A hierarchical approach to all-atom protein loop prediction. Proteins (2004) 5.18
Virtual screening of chemical libraries. Nature (2004) 4.84
Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem (2003) 4.49
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 3.92
Tools for comparative protein structure modeling and analysis. Nucleic Acids Res (2003) 3.68
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct (2003) 3.40
The maximal affinity of ligands. Proc Natl Acad Sci U S A (1999) 3.24
A model binding site for testing scoring functions in molecular docking. J Mol Biol (2002) 2.94
Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl (2002) 2.75
Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol (2004) 2.65
Docking: successes and challenges. Curr Pharm Des (2005) 2.55
Assessing scoring functions for protein-ligand interactions. J Med Chem (2004) 2.41
Virtual screening of molecular databases using a support vector machine. J Chem Inf Model (2005) 2.40
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem (2000) 2.35
Detailed analysis of scoring functions for virtual screening. J Med Chem (2001) 2.18
A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins (2004) 2.17
Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins (2004) 2.12
Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem (1999) 2.11
Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem (2005) 2.06
Nuclear hormone receptor targeted virtual screening. J Med Chem (2003) 2.05
FlexE: efficient molecular docking considering protein structure variations. J Mol Biol (2001) 2.05
Comparison of the NCI open database with seven large chemical structural databases. J Chem Inf Comput Sci (2001) 2.03
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol (2004) 1.80
An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J Chem Inf Comput Sci (2004) 1.80
Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem (2005) 1.79
Parameter estimation for scoring protein-ligand interactions using negative training data. J Med Chem (2006) 1.71
Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem (2003) 1.70
Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (2002) 1.70
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem (1999) 1.70
Virtual screening using protein-ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci (2004) 1.69
DrugScore(CSD)-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J Med Chem (2005) 1.68
Structure-based discovery of inhibitors of thymidylate synthase. Science (1993) 1.61
Matching chemistry and shape in molecular docking. Protein Eng (1993) 1.53
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol (2001) 1.52
Development of KiBank, a database supporting structure-based drug design. Comput Biol Chem (2004) 1.49
Soft docking and multiple receptor conformations in virtual screening. J Med Chem (2004) 1.47
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry (2005) 1.46
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem (2002) 1.45
Decoys for docking. J Med Chem (2005) 1.43
Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem (1999) 1.41
Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J Med Chem (2002) 1.38
Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. Proc Natl Acad Sci U S A (1991) 1.37
Consideration of molecular weight during compound selection in virtual target-based database screening. J Chem Inf Comput Sci (2003) 1.37
A comparison of methods for modeling quantitative structure-activity relationships. J Med Chem (2004) 1.36
Comparison of automated docking programs as virtual screening tools. J Med Chem (2005) 1.33
High-throughput docking as a source of novel drug leads. Curr Opin Chem Biol (2004) 1.30
Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model (2003) 1.20
Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J Med Chem (1997) 1.17
A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. Proc Natl Acad Sci U S A (1997) 1.11
Evaluation of library ranking efficacy in virtual screening. J Comput Chem (2005) 1.10
Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. J Med Chem (2004) 1.07
Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. J Am Chem Soc (2005) 1.05
Evaluation and application of multiple scoring functions for a virtual screening experiment. J Comput Aided Mol Des (2004) 1.05
A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Proteins (2005) 1.04
Kinases, homology models, and high throughput docking. J Med Chem (2003) 1.04
Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem (2005) 1.03
GAsDock: a new approach for rapid flexible docking based on an improved multi-population genetic algorithm. Bioorg Med Chem Lett (2004) 1.00
Improving structure-based virtual screening by multivariate analysis of scoring data. J Med Chem (2003) 0.97
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA. J Med Chem (2005) 0.96
Here be dragons: docking and screening in an uncharted region of chemical space. J Biomol Screen (2005) 0.94
"In situ cross-docking" to simultaneously address multiple targets. J Med Chem (2005) 0.90
Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors. J Med Chem (2005) 0.86
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem (2004) 0.85
The FlexX database docking environment--rational extraction of receptor based pharmacophores. Curr Drug Discov Technol (2004) 0.85
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem (2002) 5.67
High-throughput assays for promiscuous inhibitors. Nat Chem Biol (2005) 4.32
A specific mechanism of nonspecific inhibition. J Med Chem (2003) 3.93
Large-scale prediction and testing of drug activity on side-effect targets. Nature (2012) 3.88
Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem (2006) 3.85
Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol (2002) 3.71
Structure-based activity prediction for an enzyme of unknown function. Nature (2007) 3.65
Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem (2003) 3.44
Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol (2008) 2.98
A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem (2007) 2.97
A model binding site for testing scoring functions in molecular docking. J Mol Biol (2002) 2.94
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem (2012) 2.86
Lead discovery using molecular docking. Curr Opin Chem Biol (2002) 2.62
A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc (2006) 2.58
Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A (2009) 2.48
Predicting absolute ligand binding free energies to a simple model site. J Mol Biol (2007) 2.19
Deconstructing fragment-based inhibitor discovery. Nat Chem Biol (2006) 2.19
Automated docking screens: a feasibility study. J Med Chem (2009) 2.14
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem (2002) 2.10
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Quantifying the relationships among drug classes. J Chem Inf Model (2008) 1.92
Structural bases of stability-function tradeoffs in enzymes. J Mol Biol (2002) 1.91
Kinase inhibitors: not just for kinases anymore. J Med Chem (2003) 1.90
Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site. J Mol Biol (2009) 1.90
The Enzyme Function Initiative. Biochemistry (2011) 1.87
Predicting substrates by docking high-energy intermediates to enzyme structures. J Am Chem Soc (2006) 1.81
An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc (2002) 1.81
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem (2008) 1.81
Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem (2005) 1.79
Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc (2008) 1.74
Testing a flexible-receptor docking algorithm in a model binding site. J Mol Biol (2004) 1.73
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem (2003) 1.70
Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (2002) 1.70
Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem (2009) 1.68
Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model (2010) 1.66
Quantifying biogenic bias in screening libraries. Nat Chem Biol (2009) 1.66
A pharmacological organization of G protein-coupled receptors. Nat Methods (2013) 1.65
Protein-protein docking with multiple residue conformations and residue substitutions. Protein Sci (2002) 1.61
Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol (2009) 1.60
Rescoring docking hit lists for model cavity sites: predictions and experimental testing. J Mol Biol (2008) 1.57
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem (2010) 1.54
Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase. Structure (2002) 1.54
Soft docking and multiple receptor conformations in virtual screening. J Med Chem (2004) 1.47
Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol (2009) 1.47
In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol (2013) 1.47
Functional annotation and three-dimensional structure of Dr0930 from Deinococcus radiodurans, a close relative of phosphotriesterase in the amidohydrolase superfamily. Biochemistry (2009) 1.47
Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry (2005) 1.46
Structure-based approach for binding site identification on AmpC beta-lactamase. J Med Chem (2002) 1.45
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem (2010) 1.45
Physics-based scoring of protein-ligand complexes: enrichment of known inhibitors in large-scale virtual screening. J Chem Inf Model (2006) 1.43
Decoys for docking. J Med Chem (2005) 1.43
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem (2006) 1.42
Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc (2003) 1.41
Structural basis for imipenem inhibition of class C beta-lactamases. Antimicrob Agents Chemother (2002) 1.39
Stability and equilibria of promiscuous aggregates in high protein milieus. Mol Biosyst (2007) 1.38
Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol (2011) 1.37
Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A (2012) 1.36
Molecular docking screens using comparative models of proteins. J Chem Inf Model (2009) 1.36
Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry (2005) 1.32
The chemical basis of pharmacology. Biochemistry (2010) 1.30
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. Proteins (2002) 1.27
Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc Natl Acad Sci U S A (2012) 1.25
Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. J Mol Biol (2007) 1.22
Probing molecular docking in a charged model binding site. J Mol Biol (2006) 1.17
Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol (2012) 1.17
The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34. J Biol Chem (2002) 1.16
The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J Am Chem Soc (2006) 1.16
Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem (2013) 1.16
Structural bases for stability-function tradeoffs in antibiotic resistance. J Mol Biol (2009) 1.16
Allosteric inhibition through core disruption. J Mol Biol (2004) 1.14
Colloidal aggregation causes inhibition of G protein-coupled receptors. J Med Chem (2013) 1.13
Docking for fragment inhibitors of AmpC beta-lactamase. Proc Natl Acad Sci U S A (2009) 1.13
The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology (2010) 1.09
Resolution of chiral phosphate, phosphonate, and phosphinate esters by an enantioselective enzyme library. J Am Chem Soc (2006) 1.08
Exploiting ordered waters in molecular docking. J Med Chem (2008) 1.07